文献速递类风湿关节炎

软骨细胞通过TMEM147介导的NF-κB活化在类风湿关节炎发展中的作用

Role of Chondrocytes in the Development of Rheumatoid Arthritis Via Transmembrane Protein 147-Mediated NF-κB Activation.
PubMed 文献 · Arthritis Rheumatol · 2020-05-02

该研究探讨软骨细胞中NF-κB活化在类风湿关节炎(RA)发病中的作用,并鉴定跨膜蛋白147(TMEM147)为软骨细胞中代表性的NF-κB活化因子。结果显示RA患者和小鼠模型软骨细胞中NF-κB与STAT3共活化,TMEM147高表达,基因沉默或抗体治疗可抑制NF-κB活化和细胞因子诱导的关节炎,提示软骨细胞通过TMEM147介导的NF-κB活化参与RA发展。

要点

  • RA患者及小鼠模型软骨细胞中NF-κB与STAT3共活化,协同诱导NF-κB靶基因表达。
  • 软骨细胞特异性STAT3缺失显著抑制细胞因子诱导的RA发展。
  • 沉默TMEM147或抗TMEM147抗体可抑制NF-κB活化及体内细胞因子诱导的RA。

核心结论

  • 软骨细胞通过TMEM147介导的NF-κB活化在RA发展中发挥作用,提示新的治疗策略。

研究设计与样本

  • 研究分析RA患者临床样本(免疫组化),以多指症患者标本为对照。
  • 在多种小鼠RA模型中检查软骨细胞和TMEM147对关节炎的功能贡献。
  • 体外实验(定量PCR、RNA干扰、免疫沉淀、共聚焦显微镜)探究TMEM147在软骨细胞中的作用机制。

主要发现

  • RA患者和小鼠模型软骨细胞中NF-κB和STAT3共活化(P < 0.001)。
  • 共活化在体外协同诱导NF-κB靶基因表达(P < 0.01)。
  • 软骨细胞特异性STAT3缺失显著抑制细胞因子诱导的RA发展(P < 0.01)。
  • TMEM147在RA患者样本和小鼠模型软骨细胞中高表达。
  • 沉默TMEM147或抗TMEM147抗体治疗在体外抑制细胞因子介导的NF-κB活化(P < 0.01),在体内抑制细胞因子诱导的RA(P < 0.01)。

关键数值与推荐

  • RA患者和小鼠模型软骨细胞中NF-κB和STAT3共活化(P < 0.001)。
  • 共活化协同诱导NF-κB靶基因表达(P < 0.01)。
  • 软骨细胞特异性STAT3缺失抑制细胞因子诱导的RA(P < 0.01)。
  • 沉默TMEM147或抗TMEM147抗体抑制NF-κB活化(P < 0.01)和细胞因子诱导的RA(P < 0.01)。

临床怎么用

  • TMEM147介导的NF-κB活化可能成为RA的潜在治疗靶点。
  • 抗TMEM147抗体在动物模型中显示抑制关节炎的效果,但尚未转化至临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We have previously reported that the coactivation of NF-κB and STAT3 in nonimmune cells, including synovial fibroblasts, enhances the expression of NF-κB target genes and plays a role in chronic inflammation and rheumatoid arthritis (RA). This study was undertaken to examine the role of NF-κB activation in chondrocytes and better understand the pathogenesis of RA. Furthermore, transmembrane protein 147 (TMEM147) was investigated as a representative NF-κB activator in chondrocytes. METHODS: Clinical samples from RA patients were analyzed by immunohistochemistry. Specimens obtained from patients with polydactyly were used as control samples. The functional contribution of chondrocytes and TMEM147 to arthritis was examined in several murine models of RA. In vitro experiments (quantitative polymerase chain reaction, RNA interference, immunoprecipitation, and confocal microscopy) were performed to investigate the mechanism of action of TMEM147 in chondrocytes. RESULTS: Samples obtained from RA patients and mouse models of RA showed coactivation of NF-κB and STAT3 in chondrocytes (P < 0.001). This coactivation induced a synergistic expression of NF-κB targets in vitro (P < 0.01). Chondrocyte-specific deletion of STAT3 significantly suppressed the development of cytokine-induced RA (P < 0.01). TMEM147 was highly expressed in chondrocytes from RA patient samples and the mouse models of RA. Gene silencing of TMEM147 or anti-TMEM147 antibody treatment inhibited the cytokine-mediated activation of NF-κB in vitro (P < 0.01) and suppressed cytokine-induced RA in vivo (P < 0.01). Mechanistically, TMEM147 molecules acted as scaffold proteins for the NF-κB complex, which included breakpoint cluster region and casein kinase 2, and enhanced NF-κB activity. CONCLUSION: These results suggest that chondrocytes play a role in the development of RA via TMEM147-mediated NF-κB activation and indicate a novel therapeutic strategy for RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ota M, Tanaka Y, Nakagawa I, et al. Role of Chondrocytes in the Development of Rheumatoid Arthritis Via Transmembrane Protein 147-Mediated NF-κB Activation. Arthritis Rheumatol. 2020. PMID: 31785076. doi:10.1002/art.41182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。